FZD7 regulates BMSCs-mediated protection of CML cells

Oncotarget

Volumn 7, Issue 5, 2016, Pages 6175-6187

  Liu, Na ^a   Zang, Shaolei ^a   Liu, Yan ^a   Wang, Yingqiao ^a   Li, Wei ^a   Liu, Qiang ^b   Ji, Min ^a   Ma, Daoxin ^a   Ji, Chunyan ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

BMSCs; CML; FZD7; Imatinib sensitivity; Wnt signaling pathway

Indexed keywords

BETA CATENIN; CD34 ANTIGEN; FRIZZLED 4 PROTEIN; FRIZZLED 6 PROTEIN; FRIZZLED 7 PROTEIN; FRIZZLED PROTEIN; HERMES ANTIGEN; IMATINIB; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; REGULATOR PROTEIN; SHORT HAIRPIN RNA; SURVIVIN; TRIB2 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FZD7 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADULT; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CANCER RESISTANCE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; K562 CELL LINE; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; UPREGULATION; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BONE MARROW CELL; CASE CONTROL STUDY; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; K-562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL PROLIFERATION; DOWN-REGULATION; FRIZZLED RECEPTORS; HUMANS; IMATINIB MESYLATE; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MESENCHYMAL STROMAL CELLS; RNA, SMALL INTERFERING; TRANSFECTION; WNT SIGNALING PATHWAY;

EID: 84958078584     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6742     Document Type: Article

References (38)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341:164-172.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355:2408-2417.
3. Redner RL. Why doesn't imatinib cure chronic myeloid leukemia? Oncologist. 2010; 15:182-186.
4. Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. The one-two punch: combination treatment in chronic myeloid leukemia. Crit Rev Oncol Hematol. 2013; 88:667-679.
5. Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, Wald O, Galun E, Eizenberg O, Peled A, Nagler A. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther. 2014; 13:1155-1169.
6. Li X, Miao H, Zhang Y, Li W, Li Z, Zhou Y, Zhao L, Guo Q. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway. Arch Toxicol. 2015; 89:121-136.
7. Lien WH, Fuchs E. Wnt some lose some: transcriptional governance of stem cells by Wnt/beta-catenin signaling. Genes Dev. 2014; 28:1517-1532.
8. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999; 154:515-523.
9. Park J, Schlederer M, Schreiber M, Ice R, Merkel O, Bilban M, Hofbauer S, Kim S, Addison J, Zou J, Ji C, Bunting ST, Wang Z, et al. AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget. 2015; 6:20697-20710. doi:10.18632/oncotarget.4136.
10. Baarsma HA, Konigshoff M, Gosens R. The WNT signaling pathway from ligand secretion to gene transcription: molecular mechanisms and pharmacological targets. Pharmacol Ther. 2013; 138:66-83.
11. Wang J, Park JS, Wei Y, Rajurkar M, Cotton JL, Fan Q, Lewis BC, Ji H, Mao J. TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPalpha function. Mol Cell. 2013; 51:211-225.
12. Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, Bhatia R. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood. 2013; 121:1824-1838.
13. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122:872-884.
14. King TD, Zhang W, Suto MJ, Li Y. Frizzled7 as an emerging target for cancer therapy. Cell Signal. 2012; 24:846-851.
15. Ueno K, Hazama S, Mitomori S, Nishioka M, Suehiro Y, Hirata H, Oka M, Imai K, Dahiya R, Hinoda Y. Downregulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br J Cancer. 2009; 101:1374-1381.
16. Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, Tiede B, Romano RA, DeCoste C, Mercatali L, Ibrahim T, Amadori D, Kannan N, et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol. 2014; 16:1004-1015, 1001-1013.
17. Simmons GE, Jr., Pandey S, Nedeljkovic-Kurepa A, Saxena M, Wang A, Pruitt K. Frizzled 7 expression is positively regulated by SIRT1 and beta-catenin in breast cancer cells. PLoS One. 2014; 9:e98861.
18. Guo D, Ye J, Li L, Dai J, Ma D, Ji C. Down-regulation of Notch-1 increases co-cultured Jurkat cell sensitivity to chemotherapy. Leuk Lymphoma. 2009; 50:270-278.
19. Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, Yu E, Merle P, Wands JR. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/betacatenin signaling pathway in hepatocellular carcinoma cells. J Hepatol. 2008; 48:780-791.
20. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S, Somlo G, Yen Y. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene. 2011; 30:4437-4446.
21. Zhang Z, Rankin SA, Zorn AM. Different thresholds of Wnt-Frizzled 7 signaling coordinate proliferation, morphogenesis and fate of endoderm progenitor cells. Dev Biol. 2013; 378:1-12.
22. Chomel JC, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget. 2011; 2:713-727. doi:10.18632/oncotarget.333.
23. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle. 2005; 4:1693-1698.
24. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008; 322:1861-1865.
25. Kim JA, Shim JS, Lee GY, Yim HW, Kim TM, Kim M, Leem SH, Lee JW, Min CK, Oh IH. Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. Cancer Res. 2015; 75:2222-2231.
26. Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, Hair A, Holyoake TL, Huettner C, Bhatia R. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012; 21:577-592.
27. Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood. 2012; 119:540-550.
28. Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, Wagers AJ, Hsiao EC, Passegue E. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013; 13:285-299.
29. Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment. Br J Haematol. 2014; 164:767-778.
30. Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA, Blagosklonny MV. Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl-and Raf-1-expressing cells to imatinib and geldanamycin. Cancer Biol Ther. 2005; 4:484-490.
31. Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells. Oncotarget. 2014; 5:8637-8650. doi:10.18632/oncotarget.2353.
32. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351:657-667.
33. Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol. 2008; 35:S1-17; quiz S18-20.
34. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007; 12:528-541.
35. Hu Y, Chen Y, Douglas L, Li S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 2009; 23:109-116.
36. Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW, Armstrong SA. Genetic and pharmacologic inhibition of beta-catenin targets imatinibresistant leukemia stem cells in CML. Cell Stem Cell. 2012; 10:412-424.
37. Coluccia AM, Vacca A, Dunach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 2007; 26:1456-1466.
38. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006; 66:6468-6472.